Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has secured US Medicare reimbursement eligibility for eligible procedures ...
Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical ...
Anteris Technologies is developing DurAVR, a differentiated biomimetic TAVR device with encouraging early clinical data in ...
Today, Paradigm Health announced the launch of a landmark research collaboration with the U.S. Food & Drug Administration (FDA) focused on advancing a new model to accelerate clinical trial execution ...
The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower ...
Late-stage drug developer Paradigm Biopharmaceuticals (ASX:PAR) has announced its pivotal Phase 3 PARA_OA_012 clinical trial ...
Paradigm Health today announced SPIRE -- Scalable Platform for Integrated Research & Evidence -- a new model for post-approval and late-stage clinical studies designed to help sponsors generate ...
The late-stage developer of a drug for knee osteoarthritis, Paradigm Biopharmaceuticals has increased its placement from $8 ...
Intermittent dosing with rapamycin selectively breaks the cascade of inflammatory events that follow cellular senescence, a phenomena in which cells cease to divide in response to DNA damaging agents, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results